The once-daily human GLP-1 analogue liraglutide improves both absolute and baseline corrected postprandial glucose levels

被引：0
|
作者：
Flint, A. [1 ]
Kapitza, C. [2 ]
Hindsberger, C. [1 ]
Zdravkovic, M. [1 ]
机构：
[1] Novo Nordisk AS, Global Dev, DK-2880 Bagsvaerd, Denmark
[2] Profil Inst Stoffivechselforsch GmbH, Neuss, Germany
来源：
DIABETOLOGIA | 2008年 / 51卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
887
引用
收藏
页码：S354 / S354
页数：1
相关论文
共 50 条
  • [31] Greater glycaemic control is achieved with the once-daily human GLP-1 analogue liraglutide vs comparators across the continuum of estimated beta cell mass
    Meier, J. J.
    Vilsboll, T.
    Donsmark, M.
    Hartvig, H.
    Nauck, M. A.
    DIABETOLOGIA, 2011, 54 : S322 - S322
  • [32] Patient-reported rating of gastrointestinal adverse effects during treatment of type 2 diabetes with the once-daily human GLP-1 analogue, liraglutide
    Horowitz, M.
    Vilsboll, T.
    Zdravkovic, M.
    Hammer, M.
    Madsbad, S.
    DIABETES OBESITY & METABOLISM, 2008, 10 (07): : 593 - U4
  • [33] Metabolism and excretion of the once-daily human GLP-1 analogue liraglutide in healthy subject and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase
    Bjornsdottir, I.
    Olsen, A.
    Larsen, U.
    Helleberg, H.
    Vanggaard, J.
    Oosterhuis, B.
    van Lier, J.
    Zdravkovic, M.
    Malm-Erjefalt, M.
    DIABETOLOGIA, 2008, 51 : S356 - S356
  • [34] Once daily dosing of the long acting GLP-1 analogue liraglutide significantly improves glycaemic control by reducing both fasting and post-prandial glucose levels in Japanese subjects with type 2 diabetes
    Seino, Yutaka
    Kaku, Kohei
    Nishijima, Keiji
    Rasmussen, Mads F.
    Zdravkovic, Milan
    Kristensen, Peter
    DIABETES, 2007, 56 : A138 - A139
  • [35] The once-daily human GLP-1 analog liraglutide reduces body weight in subjects with type 2 diabetes, irrespective of body mass index at baseline
    Russell-Jones, David
    Shaw, Jonathan E.
    Brandle, Michael
    Matthews, David
    Frid, Anders
    Zdravkovic, Milan
    Schmitz, Ole
    DIABETES, 2008, 57 : A593 - A594
  • [36] Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide
    Astrup, A.
    Carraro, R.
    Finer, N.
    Harper, A.
    Kunesova, M.
    Lean, M. E. J.
    Niskanen, L.
    Rasmussen, M. F.
    Rissanen, A.
    Rossner, S.
    Savolainen, M. J.
    Van Gaal, L.
    INTERNATIONAL JOURNAL OF OBESITY, 2012, 36 (06) : 843 - 854
  • [37] Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide
    A Astrup
    R Carraro
    N Finer
    A Harper
    M Kunesova
    M E J Lean
    L Niskanen
    M F Rasmussen
    A Rissanen
    S Rössner
    M J Savolainen
    L Van Gaal
    International Journal of Obesity, 2012, 36 : 843 - 854
  • [38] Liraglutide: A once-daily human glucagon-like peptide-1 analogue
    Aimaretti, G.
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2009, 32 (08) : 701 - 703
  • [39] Liraglutide: A once-daily human glucagon-like peptide-1 analogue
    G. Aimaretti
    Journal of Endocrinological Investigation, 2009, 32 : 701 - 703
  • [40] Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analogue, liraglutide (vol 36, pg 890, 2012)
    Astrup, A.
    Carraro, R.
    Finer, N.
    Harper, A.
    Kunesova, M.
    Lean, M. E. J.
    Niskanen, L.
    Rasmussen, M. F.
    Rissanen, A.
    Roessner, S.
    Savolainen, M. J.
    Van Gaal, L.
    INTERNATIONAL JOURNAL OF OBESITY, 2012, 36 (06) : 890 - 890
12345